Dupilumab
R668-EE-1877
Phase 3 small_molecule active
Quick answer
Dupilumab for Eosinophilic Esophagitis (EoE) is a Phase 3 program (small_molecule) at Regeneron UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Eosinophilic Esophagitis (EoE)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active